OncoMatch/Clinical Trials/NCT06969612
A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC
Is NCT06969612 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments for nsclc (advanced non-small cell lung cancer).
Treatment: Tislelizumab · Pemetrexed · Cisplatin · Carboplatin · Paclitaxel · Albumin Paclitaxel · Golidocitinib — The goal of this clinical trial is to learn if golidocitinib combined with tislelizumab and chemotherapy works in advanced NSCLC with PD-L1≥1%. The main question it aims to answer is: Does the combination of golidocitinib with tislelizumab and chemotherapy can prolong the progression-free survival of patients with advanced NSCLC? Participants will： Take tislelizumab and chemotherapy for 2 cycles; and then take tislelizumab and golidocitinib for 2 cycles; after cycle 5, patients receive tislelizumab and chemotherapy until the patients were intolerant or the disease progressed.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR exon 19 deletion
Histology of lung adenocarcinoma confirmed the presence of EGFR19 deletion or L858R mutation and ALK, ROS-1 fusion gene mutation (non-adenocarcinoma patients are not required to undergo mandatory genetic testing).
Required: EGFR L858R mutation
Histology of lung adenocarcinoma confirmed the presence of EGFR19 deletion or L858R mutation and ALK, ROS-1 fusion gene mutation (non-adenocarcinoma patients are not required to undergo mandatory genetic testing).
Required: ALK fusion gene mutation
Histology of lung adenocarcinoma confirmed the presence of EGFR19 deletion or L858R mutation and ALK, ROS-1 fusion gene mutation (non-adenocarcinoma patients are not required to undergo mandatory genetic testing).
Required: ROS1 fusion gene mutation
Histology of lung adenocarcinoma confirmed the presence of EGFR19 deletion or L858R mutation and ALK, ROS-1 fusion gene mutation (non-adenocarcinoma patients are not required to undergo mandatory genetic testing).
Required: PD-L1 (CD274) PD-L1(22C3) ≥1% (≥1%)
PD-L1(22C3) ≥1%
Disease stage
Required: Stage IIIB, IIIC, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic chemotherapy
Cannot have received: biological therapy
Cannot have received: targeted therapy
Cannot have received: immunotherapy
Lab requirements
Blood counts
ANC ≥ 1.5×10^9/L (no growth factor); platelets ≥ 100×10^9/L (no growth factor or transfusion); hemoglobin ≥ 9 g/dL (no transfusion or erythropoietin)
Kidney function
Blood creatinine ≤ 1.5 × ULN, or creatinine clearance rate ≥ 50 mL/min (Cockcroft-Gault or 24h urine)
Liver function
Total bilirubin ≤ 1.5 × ULN (≤ 3 × ULN if Gilbert syndrome); ALT and AST ≤ 2.5 × ULN (≤ 5 × ULN with liver metastases)
The bone marrow reserve and organ system functional reserve are sufficient...see full details above
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06969612 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require EGFR?
Yes, EGFR exon 19 deletion is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR L858R mutation is a required biomarker for enrollment.
Does this trial require ALK?
Yes, ALK fusion gene mutation is a required biomarker for enrollment.
What disease stage is eligible?
Stage IIIB or IIIC or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify